Maribavir

(Livtencity®)

Livtencity®

Drug updated on 10/25/2024

Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Maribavir has been approved for the treatment of post-transplant cytomegalovirus (CMV) infection or disease, specifically in adolescents, demonstrating its effectiveness in this population.
  • Maribavir has shown effectiveness in managing refractory or resistant CMV infections in transplant recipients, making it a valuable option for patients whose infections do not respond to other treatments.
  • No significant differences in effectiveness among different population types or subgroups for maribavir were reported in the reviewed studies.
  • There is no specific safety information available for maribavir in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Livtencity (maribavir) Prescribing Information.2024Takeda Pharmaceuticals America Inc., Lexington, MA

Systematic Reviews / Meta-Analyses